Beef Prices: Blame the Packers, Not America’s Ranchers
KEY POINTS Beef prices are at record highs—not because of U.S. ranchers or tariffs, but because dependence on foreign imports and meatpacker consolidation have distorted
At Senate Commerce, Bipartisan Support for Shipbuilding Industry. So What is Congress Waiting For?
There are very few things that Democrats and Republicans agree on. One of them is the need to support domestic shipbuilding beyond just military vessels.
CPA Releases New Economics Report on America’s Chip-for-Chip Tariff Policy
The report, titled “America’s Chip-for-Chip Tariff Policy: The Urgent Fight to Reclaim Industrial Independence Before It’s Too Late,” finds that the United States now produces only 10 percent of the world’s chips—and almost none of the most advanced ones—while China has captured the majority of global capacity for legacy chips, the mature semiconductors essential to cars, medical devices, and industrial equipment.
No, America is Not Too Economically Successful to Need Reform
On the surface, America looks like an unrivaled success story. Yet beneath the headline numbers lies an economy increasingly dependent on foreign production, hollowed out in critical industries, and unable to provide secure, high-wage work for many of its citizens.
To Reshore Generic Drugs, Use Sugar’s Sweet Model
America is finally getting serious about its dangerous dependence on foreign-made generic drugs.
GM Tops the List of “Most Exposed to China”
This year, GM swapped positions with Ford. GM is the most exposed to China while Ford has declined to No. 5.
CPA’s Jeff Ferry Teaches the Next Generation How to Rebuild American Industry
CPA’s chief economist emeritus, Jeff Ferry, has gone back to school in his semi-retirement years. This time, though, it was a speaking gig at the University of Florida’s new Semiconductor Institute in Gainesville.
CPA Economist Leads Rare Bipartisan Push to Fix America’s Generic Drug Crisis
CPA Economist Andrew Rechenberg gave his testimony and answered questions in a four- panelist hearing. It was arguably the most agreeable hearing in years. A bipartisan consensus on America’s generic drug supply chain is nearly fully formed now.
New CPA Economic Report on ‘The New Biotech Cold War’
Titled “The New Biotech Cold War: The U.S. Medicine Can’t Afford to Fall Behind China,” the report shows how U.S. biotech – long a pillar of national strength – no longer has a guaranteed edge globally.
Pharmaceutical 232 Must Cover Generic Drugs to Fulfill President’s Promise of Reshoring Essential Medicine Production
The Trump administration’s Section 232 investigation into pharmaceutical imports is reportedly close to being final. The final investigation’s success will depend largely on whether or not the Commerce Department determines that there is a crisis in the generics industry — an issue that President Trump highlighted back in 2023.
